

Special Issue

Inequality in Immunization 2025

Message from the Guest Editors

Significant progress has been made in improving access to immunization worldwide, particularly for children. However, the benefits of increased vaccine access are not evenly distributed within or across countries. Research and monitoring have identified persistent and emerging gaps in both childhood and adult immunization, influenced by factors such as socioeconomic status, place of residence, and gender. These have been examined in previous Special Issues of *Vaccines* in 2023 and 2024, which showcased advancements in our understanding of immunization inequalities and presented options for immunization delivery that offer promise in addressing disparities. Emerging challenges like vaccine refusal and hesitancy exacerbate vaccine inequalities during times of reform, stability, and crisis. In the latest Special Issue on Inequality in Immunization, the third in our series, we aim to expand the existing body of evidence. We welcome research and review articles that explore immunization inequalities and articles that effectively address these inequities in meaningful and lasting ways.

Guest Editors

Dr. Ahmad Reza Hosseinpour

Dr. Devaki Nambiar

Dr. Nicole Bergen

Dr. M. Carolina Danovaro

Dr. Hope L. Johnson

Dr. Ibrahim Dadari

Deadline for manuscript submissions

15 September 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/227993

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).